NASDAQ:CYCN
Cyclerion Therapeutics, Inc.
- Stock
Last Close
2.83
24/09 20:00
Market Cap
10.33M
Beta: 1.94
Volume Today
18
Avg: 293.75K
PE Ratio
−0.66
PFCF: −0.26
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|
average inventory | 983K - | 1.39M 41.51% | 872K 37.31% | 866.50K 0.63% | 402.50K 53.55% | |||
average payables | 2.29M - | 3.05M 32.93% | 2.37M 22.09% | 1.63M 31.25% | 2.40M 47.04% | 2.08M 13.13% | ||
average receivables | 737K - | 800.50K 8.62% | 113.50K 85.82% | 98K 13.66% | 48K 51.02% | |||
book value per share | -6.28 - | -7.65 21.92% | 71.39 1,033.07% | 39.14 45.18% | 24.65 37.01% | 0.34 98.61% | 4.83 1,304.40% | |
capex per share | -1.03 - | -2.52 144.87% | -5.03 99.80% | -1.00 80.07% | -0.00 99.64% | |||
capex to depreciation | -0.80 - | -2.25 179.65% | -2.55 13.38% | -0.66 73.99% | -0.01 97.76% | |||
capex to operating cash flow | 0.02 - | 0.04 103.97% | 0.07 91.11% | 0.02 68.80% | 0.00 99.09% | |||
capex to revenue | -1.53 - | -0.66 56.57% | -0.00 99.68% | |||||
cash per share | 69.32 - | 35.78 48.38% | 27.57 22.95% | 0.44 98.40% | 3.24 635.71% | |||
days of inventory on hand | ||||||||
days payables outstanding | ||||||||
days sales outstanding | 119.37 - | 20.19 83.09% | 10.99 45.55% | 117.98 973.13% | ||||
debt to assets | 0.40 - | 0.40 0.00% | ||||||
debt to equity | 0.76 - | 0.77 1.64% | ||||||
dividend yield | ||||||||
earnings yield | -0.28 - | -0.34 22.71% | -1.62 381.06% | -0.78 51.91% | -0.77 1.76% | -0.11 85.70% | -0.67 512.37% | |
enterprise value | 341.30M - | 341.31M 0.00% | 53.50M 84.33% | 84.37M 57.71% | 13.37M 84.16% | 385.63M 2,784.99% | 261.30K 99.93% | |
enterprise value over ebitda | -3.70 - | -3.00 18.95% | -0.44 85.43% | -0.99 126.50% | -0.25 74.94% | -8.70 3,405.84% | -0.02 99.77% | |
ev to operating cash flow | -4.20 - | -3.50 16.70% | -0.52 85.05% | -1.16 122.38% | -0.37 68.55% | -9.50 2,494.15% | -0.01 99.87% | |
ev to sales | 11.87 - | 36.75 209.58% | 4.03 89.04% | 1.30K 32,149.69% | ||||
free cash flow per share | -60.52 - | -73.94 22.17% | -79.70 7.79% | -48.69 38.91% | -18.66 61.67% | -1.34 92.84% | -9.09 580.28% | |
free cash flow yield | -0.24 - | -0.30 22.17% | -1.46 395.35% | -0.80 45.69% | -0.54 31.81% | -0.10 81.24% | -2.71 2,565.06% | |
graham net net | -10.28 - | -13.07 27.13% | 6.01 146.01% | -0.65 110.79% | 22.18 3,517.31% | 0.20 99.08% | 2.35 1,044.97% | |
graham number | 98.56 - | 120.55 22.31% | 376.75 212.53% | 205.17 45.54% | 121.00 41.03% | 3.34 97.24% | 15.64 368.53% | |
income quality | 0.86 - | 0.85 2.17% | 0.83 1.78% | 0.93 12.13% | 0.71 24.11% | 0.92 30.31% | 4.04 338.13% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | 0 | |
interest coverage | -3.45K - | -150.93 95.62% | ||||||
interest debt per share | 54.00 - | 30.09 44.28% | 0.01 99.97% | 0.01 18.29% | ||||
inventory turnover | ||||||||
invested capital | 0.76 - | 0.77 1.64% | ||||||
market cap | 341.30M - | 341.31M 0.00% | 74.47M 78.18% | 93.03M 24.92% | 67.33M 27.63% | 399.01M 492.64% | 7.83M 98.04% | |
net current asset value | -12.78M - | -16.97M 32.78% | 12.45M 173.37% | 2.62M 78.98% | 44.37M 1,596.18% | 7.19M 83.79% | 5.94M 17.45% | |
net debt to ebitda | 0.17 - | 0.10 40.70% | 1.00 885.79% | 0.30 69.86% | 0.58 93.55% | |||
net income per share | -68.80 - | -84.42 22.71% | -88.37 4.68% | -47.80 45.90% | -26.40 44.78% | -1.44 94.54% | -2.25 56.31% | |
operating cash flow per share | -59.49 - | -71.42 20.05% | -74.66 4.54% | -47.69 36.13% | -18.66 60.87% | -1.34 92.84% | -9.09 580.28% | |
payables turnover | ||||||||
receivables turnover | 3.06 - | 18.08 491.26% | 33.20 83.64% | 3.09 90.68% | ||||
research and ddevelopement to revenue | 21.11 - | 24.57 16.40% | 11.34 53.86% | 106.04 835.39% | ||||
return on tangible assets | -17.17 - | -15.57 9.31% | -0.65 95.83% | -0.63 2.92% | -0.87 38.25% | -2.42 178.13% | -0.39 83.75% | |
revenue per share | 3.29 - | 1.51 54.12% | 1.70 12.31% | 0.01 99.42% | ||||
roe | 10.96 - | 11.03 0.65% | -1.24 111.22% | -1.22 1.33% | -1.07 12.33% | -4.19 291.20% | -0.47 88.87% | |
roic | 10.96 - | 11.03 0.65% | -0.50 104.54% | -0.51 2.79% | -1.14 122.31% | -4.22 268.49% | -1.15 72.79% | |
sales general and administrative to revenue | 7.63 - | 12.55 64.41% | 6.21 50.51% | 48.84 686.29% | ||||
shareholders equity per share | -6.28 - | -7.65 21.92% | 71.39 1,033.07% | 39.14 45.18% | 24.65 37.01% | 0.34 98.61% | 4.83 1,304.40% | |
stock based compensation to revenue | 4.36 - | 6.53 49.91% | 2.89 55.67% | 21.05 627.16% | ||||
tangible asset value | -8.57M - | -10.45M 21.92% | 97.73M 1,035.65% | 59.49M 39.12% | 48.25M 18.90% | 10.45M 78.34% | 11.29M 8.00% | |
tangible book value per share | -6.28 - | -7.65 21.92% | 71.39 1,033.07% | 39.14 45.18% | 24.65 37.01% | 0.34 98.61% | 4.83 1,304.40% | |
working capital | -12.78M - | -16.97M 32.78% | 82.95M 588.88% | 41.55M 49.91% | 44.37M 6.79% | 7.19M 83.79% | 5.94M 17.45% |
All numbers in USD (except ratios and percentages)